Taxol dose intensification and its clinical implications.
Taxol is the most exciting new anticancer agent developed in the past two decades. Of great interest is its level of activity in ovarian cancer, as well as substantial activity in breast cancer, nonsmall-cell lung cancer, melanoma, and other malignancies. Recent studies suggest that when taxol is administered in a fashion to increase milligram dosage per unit time (mg/m2/week), the response rate in patients with ovarian cancer is markedly increased. This article reviews studies that suggest taxol dose intensity is important in the treatment of patients with ovarian cancer.
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (931K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
These references are in PubMed. This may not be the complete list of references from this article.
- Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990 Aug 1;82(15):1247–1259. [PubMed] [Google Scholar]
- McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. [PubMed] [Google Scholar]
- Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol. 1987 Aug;5(8):1232–1239. [PubMed] [Google Scholar]
- Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec 18;83(24):1797–1805. [PubMed] [Google Scholar]
- Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 1987 May 1;47(9):2486–2493. [PubMed] [Google Scholar]
- Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res. 1989 Aug 15;49(16):4640–4647. [PubMed] [Google Scholar]
- Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep. 1987 Dec;71(12):1171–1177. [PubMed] [Google Scholar]
- Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991 Sep;9(9):1704–1712. [PubMed] [Google Scholar]
- Simone JV, Meyer WH, Link MP. Osteosarcoma: good news despite crude tools. J Clin Oncol. 1992 Jan;10(1):1–2. [PubMed] [Google Scholar]
- Lipton RB, Apfel SC, Dutcher JP, Rosenberg R, Kaplan J, Berger A, Einzig AI, Wiernik P, Schaumburg HH. Taxol produces a predominantly sensory neuropathy. Neurology. 1989 Mar;39(3):368–373. [PubMed] [Google Scholar]
- Einzig AI, Gorowski E, Sasloff J, Wiernik PH. Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest. 1991;9(2):133–136. [PubMed] [Google Scholar]